Previous close | 1.4205 |
Open | 1.5130 |
Bid | 0.0000 x N/A |
Ask | 0.0000 x N/A |
Day's range | 1.5050 - 1.6199 |
52-week range | 1.1020 - 7.6000 |
Volume | |
Avg. volume | 6,355 |
Market cap | 82.692M |
Beta (5Y monthly) | 1.69 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.0490 |
Earnings date | 07 Aug 2024 - 12 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
We recently compiled a list of the 10 Best One-Dollar Stocks To Buy Now. In this article, we are going to take a look at where Adicet Bio, Inc. (NASDAQ:ACET) stands against the other one-dollar stocks. The upward trend in the stock market has resumed, supported by strong first-quarter and second-quarter results that have relieved […]
Key Insights Given the large stake in the stock by institutions, Adicet Bio's stock price might be vulnerable to their...
REDWOOD CITY, Calif. & BOSTON, July 08, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ADI-270 for the potential treatment of patients with metastatic/advanced clear cell renal cell carcinoma (ccRCC) who have been treated with an immune checkpoint inhibitor and a vasc